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ANALYSIS OF MEFV GENE EXPRESSION AND METHYLATION 
PATTERNS IN FAMILIAL MEDITERRANEAN FEVER 
SUMMARY 
MEFV is the first identified autoinflammatory gene for Familial Mediterranean 
Fever (FMF). FMF mainly affects people of Mediterranean ancestry, generally 
Turks, non-Ashkenazi Jews, Armenians and Arabs. The most common MEFV 
mutations are M694V, M680I, M694I, V726A and E148Q, which are attributed to 
about 70% of disease-associated alleles. Among these mutations, E148Q, located at 
the second exon of MEFV, is associated with a milder phenotype of the disease. 
Although the expression level of gene is lower in other mutant allele carriers, it is 
shown that E148Q mutation increases the expression level of MEFV.  
Bioinformatic analysis of MEFV gene has shown the presence of CpG island 
spanning the second exon and a part of first intron of gene covering a 998 bp region. 
E148Q mutation occurs within this CpG island. DNA methylation is an important 
epigenetic regulation which affects gene expression patterns. Since the lower 
expression level of MEFV is known to be associated with acute inflammation, we 
wanted to know whether the methylation in the second exon of MEFV is correlated 
with the expression of the mRNA as well as its relevance to FMF disease. We 
studied 51 child FMF patients from Cerrahpaşa Medical Faculty department of 
Pediatrics and 11 healthy controls from the same department. The methylation levels 
of the second exon of MEFV gene were quantified by MethyLight technique, which 
is a probe-based real-time PCR method using the genomic DNA as a template. 
Expression levels were quantified using real-time PCR methods from blood RNA 
samples. MEFV cDNA reporter gene constructs containing exon 2 variants, were 
also transfected in HeLa cells, and expression levels in vitro were determined. 
In this study, 33 of 51 FMF patients had mutations (59.4% mutant allele) and four of 
11 healthy controls had mutant alleles (22.7% mutant allele). These results show 
significant difference between the mutation frequency in FMF patients and healthy 
controls as expected (p= 0.0016, Odds Ratio: 2.7689). Our expression results indicate 
that, compared to healthy controls (p=0.031), mRNA levels were decreased two-fold 
in FMF patients . In accordance, methylation status of second exon of MEFV were 
slightly higher in FMF patients compared to healthy controls, but there were no 
significant differences between the two groups. On the other hand, in vitro studies 
indicated increased expression from the construct lacking exon 2, compared to the 
one with parts of the exon 2 (p=0.0013), which indicate the importance of 
methylation interference with mRNA expression.  
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AİLESEL AKDENİZ ATEŞİ HASTALIĞINDA MEFV GEN EKSPRESYONU 
VE METİLASYON ANALİZLERİ 
ÖZET 
MEFV, Ailevi Akdeniz Ateşi (AAA) hastalığı ile ilişkilendirilmiş ilk 
otoinflammatuar gendir. AAA çoğunlukla Türkler, aşkenaz olmayan yahudiler, 
Ermeniler ve Araplar gibi akdeniz kökenli toplumlarında görülmektedir. En sık 
görülen mutasyonlar, M694V, M680I, M694I, V726A ve E148Q hastalıkla ilişkili 
allellerin yaklaşık %70’ini oluşturmaktadır. Bu mutasyonların içinden MEFV 
geninin ikinci ekzonunda bulunan E148Q mutasyonunun hastalığın daha hafif bir 
şekilde geçirilmesiyle ilişkili olduğu görülmüştür. E148Q mutasyonu dışındaki 
mutasyonları taşıyanlarda MEFV gen ifade seviyesinin daha az olmasına karşın 
E148Q mutasyonu taşıyanlarda MEFV gen ifadesinin arttığı gösterilmiştir. 
MEFV geni için yapılan bioinformatik analizler sonucunda, genin ikinci ekzonunu ve 
birinci intronun bir kısmını içeren 998 bç uzunluğundaki bölgeye yayılmış olan bir 
CpG adacığı tespit edilmiştir. E148Q mutasyonu bu CpG adacığı içerisinde bir 
bölgede gerçekleşmektedir. DNA metilasyonu gen ifadesini etkileyen önemli 
epigenetik mekanizmalardan birisidir. Düşmüş olan MEFV gen ifadesi miktarının 
akut inflammasyonla ilişkili olduğu bilinmektedir. Bu nedenle biz MEFV geninin 
ikinci ekzonunda ki metilasyonun gen ifadesini düzenleyip düzenlemediğini ve 
hastalığın gelişiminde etkin olup olmadığını bilmek istiyoruz. Cerrahpaşa Tıp 
Fakültesi, Çocuk Sağlığı ve Hastalıkları anabilim dalına başvuran 51 FMF hastası ve 
11 sağlıklı kontrolde çalışma yapıldı. Probe kullanılarak yapılan tam zamanlı 
polimeraz zincir reaksiyonunu (qRT-PCR) temel alan bir metod olan “MethyLight” 
yöntemi ile genomik DNA kalıp olarak kullanılarak, ikinci ekzondaki metilasyon 
miktarı belirlenmiştir. Kandan elde edilen RNA’dan, MEFV gen ifade seviyesi tam 
zamanlı PZR yöntemi kullanılarak belirlenmiştir. Ayrıca ikinci ekzon varyantlarını 
içeren MEFV cDNA raportör gen konstarktı HeLa hücrelerine transfekte edildi ve in 
vitro olarak ekspresyon seviyesi belirlendi.  
Bu çalışmada 51 FMF hastasından 33 tanesinin (%59.4 mutant allel), 11 sağlıklı 
kontrolden 4 tanesinin (%22.4 mutant allel) mutant alleli taşıdığı gösterildi. Bu 
sonuçlar beklenildiği gibi iki grup arasında anlamlı bir fark olduğunu göstermektedir 
(p= 0.0016, Odds Ratio: 2.7689). Sonuçlar AAA hastalarında, sağlıklılara oranla 
yaklaşık iki kat azalmış MEFV ekspresyon miktarını göstermektedir (p=0.031). FMF 
hastaları ve sağlıklı kontrollerde metilasyon durumuna bakıldığında, iki grup 
arasında istatistiksel olarak anlamlı bir fark bulunmamasına karşın, FMF hastalarında 
metilasyonun sağlılıklara göre biraz daha yüksek olduğu gözlendi. Buna karşın in 
vitro çalışmalarda, ikinci ekzonu içermeyen MEFV cDNA ile transfekte edilmiş 
hücrelerde, ikinci ekzonu içeren hücrelere oranla, ekspresyonun anlamlı olarak arttığı 
gösterildi (p=0.0013). Bu sonuçlar MEFV geninin 2. ekzonundaki metilasyonun, gen 
ifade seviyesi üzerindeki önemini göstermektedir. 
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1.  INTRODUCTION 
1.1 MEFV Gene and Familial Mediterranean Fever Disease 
MEFV (MEditerranean FeVer) gene is an autoinflammatory gene which has been 
introduced as candidate gene for FMF.  International FMF Consortium identified 
MEFV (MEditerranean FeVer) by positional cloning [1]. Same year, the region of 60 
kb and four different mRNA’s, which comprise MEFV, were reported by The French 
FMF Consortium [2]. MEFV gene is located on chromosome 16p between D16S80 
and D16S283 and consists 10 exons (Figure 1.1). MEFV encodes 3.7 kb transcripts, 
which are mainly expressed in neutrophils, eosinophils, cytokine activated 
monocytes, dendritic cells and synovial fibroblasts [3]. The expression of MEFV is 
increased by proinflammatory agents which are interferon γ (IFN-γ), tumor necrosis 
factor α (TNF-α), lipopolysaccharide (LPS) and interleukin 1β (IL-1β) [4]. Several 
different isoforms of MEFV were shown previous studies. One of them is MEFV-fl, 
which encodes full-length pyrin, and other isoform is MEFV-d2 which produce 2nd 
exon spliced form of pyrin [5]. Another form of MEFV is MEFV-8ext involving a 
part of the following intron, which encodes truncated protein. In addition, similar 
forms of MEFV, MEFV-4a and MEFV-2a have part of following introns [6]. It is 
shown that full-length pyrin, which consists of 781 amino acids is located cytoplasm 
and related with microtubule and actin filaments by B30.2 domain of pyrin. 
Alternatively spliced form of pyrin, which is 570 amino acids long is located mainly 
at the nucleus [7].  
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Figure 1.1 : Schematic presentation of MEFV gene (17) 
Familial Mediterranean Fever (FMF) is the most common inherited periodic fever 
syndrome, also known as autoinflammatory disorder. The disease affects people of 
Mediterranean ancestry, mostly Turks, non-Ashkenazi Jews, Armenians and Arabs 
[3]. The frequency of FMF in Turkish population is 1/1073; however, it increases to 
1/395 in the interior regions of Turkey [8]. The carrier frequency in Mediterranean 
population is between 1/8 and 1/16 [9]. Typical symptoms of FMF disease are 
recurrent attacks of fever, inflammation of peritoneum, synovium or pleura, 
accompanied by abdominal pain. The major complication in untreated cases is 
development of amyloidosis which is generally affecting kidneys and sometimes 
adrenals, intestine, spleen, lung and testis [10]. Diagnosis is based on clinical criteria, 
family history and laboratory results such as leukocytosis, elevated C – reactive 
protein (CRP) and sedimentation rate during attacks. Additionally, MEFV mutations 
are analyzed to support diagnosis. Colchicine is the only effective treatment to 
relieve FMF attacks and to prevent amyloidosis [11]. 
1.2 Function of MEFV Gene and Its product; Pyrin 
1.2.1 MEFV Mutations 
Until today, 187 sequence variations are identified on MEFV gene. 73 of these 
variations have been reported to be associated with FMF [12]. Mutations are located 
in exons 1, 2, 3, 5, 9 and 10 of MEFV. Two mutational hot spots have been 
identified: one in exon 2 and one in exon 10 (Figure 1.2). The most common 
mutations which are attributed to 70% of disease associated alleles are; M694V, 
M694I, M680I, V726A and E148Q [13]. However, E148Q mutation is located at the 
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second exon of MEFV and other mutations are reported to be located at the tenth 
exon of the gene, which corresponds to B30.2 domain of pyrin protein [14]. 
 
Figure 1.2 : MEFV mutations [12] 
Although FMF is known as an autosomal recessive disorder, dominant or compound 
heterozygote transmissions have been reported. There are also some cases, which do 
not have any mutations [14]. Until now the genotype-phenotype correlation has not 
been clarified, nevertheless existence of ideas about relation between type of the 
mutation and symptoms of FMF are present [15]. The most common mutation 
M694V in FMF patients with ranging from 20 to 60% allele frequency is thought to 
be a crucial risk for the development of amyloidosis, arthritis and increased 
frequency of attacks [14]. E148Q (12%) which is associated with the milder 
phenotype in FMF patients represents the most common gene variation among 
healthy individuals. According to Akin et. al. four mutations that have high 
frequency among 12 mutations in FMF patients are M694V (47.60%), E148Q 
(16.75%), V726A (12.96%) and M680I (11.94%). Also MEFV mutation frequency 
in healthy Turkish population was reported as 20% by Yılmaz E. et. al. [15].  
In recent studies, it has been reported that there is association between MEFV gene 
variations and other autoinflammatory disorders such as Behçet’s disease (BD) [16, 
17], rheumatoid arthritis (RA) [18] and inflammatory bowel disease (IBD) [19]. 
MEFV mutations were found to be more present in BD. Ayesh et. al. reported that 
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40.5% of the patients have nine different MEFV variations. E148Q was found to be 
the most common mutation with frequency of 38.1% of mutated alleles [16, 17]. 
Additionally, Rabinovich et. al. found that 17% of RA patients have common MEFV 
mutations with the high frequency E148Q mutation (12/98 patients). After these 
evidences, it is thought that MEFV gene has a major role in the inflammatory 
pathway [20].  
1.2.2 MEFV Expression 
Several gene expression studies have reported the association between MEFV 
mutations and MEFV expression levels. In 2002, Notarnicola et. al. studied the 
relationship between mRNA level of MEFV gene and MEFV mutations. They found 
lower mRNA levels of MEFV in FMF patients compared to healthy controls and 
intermediate mRNA levels in healthy carriers. Besides, they showed that M694V 
mutation is associated to low MEFV expression levels and MEFV mRNA level is 
also decreased by increasing mutation numbers. The FMF patients with E148Q 
mutation who have milder symptoms showed higher mRNA levels than other 
patients [21]. A second study, by Ustek et. al. was confirmed the previous study 
results; decreased mRNA levels of MEFV in FMF patients compared to healthy 
controls. Besides, they showed that the expression levels of MEFV gene is more 
reduced in FMF patients during attacks. They indicated that the lower mRNA levels 
of MEFV are related to inflammation [22]. 
Booty et. al. analyzed the allelic expressions of MEFV in three different groups from 
8 FMF patients and found that the expression levels of the gene in healthy controls 
and patients with one mutation and patients with two mutations are not significantly 
different. Despite of the previous two studies, MEFV expression was found slightly 
higher in the FMF patients than healthy controls. To confirm these results, they 
examined pyrin levels in granulocytes by Western blot analysis and found significant 
increase in pyrin levels between FMF patients and healthy controls. On the other 
hand, they did not find any differences between patients with 1 and 2 mutations [22]. 
Several alternatively spliced forms of MEFV gene were shown recent studies. 
Alternative splicing and nonsense-mediated decay (NMD) have role at the post-
transcriptional regulation of gene expression. Grandemange et. al. showed that NMD 
regulates the expression of MEFV by inhibition of  NMD using CHX which is 
 5
protein translator inhibitor or siRNA. They also investigated that alternative spliced 
forms of MEFV encodes different protein isoforms which exists different cellular 
localization [23]. 
1.2.3 The Gene Product of MEFV – Pyrin/Marenostrin 
The translational product of MEFV is called pyrin/marenostrin. Pyrin protein 
consists of five domains which are (I) N-terminal PYRIN domain (also known as 
PYD, PAAD, DAPIN), (II) bZIP transcription factor basic domain, (III) B-Box zinc 
domain, (IV) α-helical (coiled-coil) domain (CC), (5) C-terminal B30.2 domain 
(PRYSPRY) which corresponds tenth exon of MEFV gene (Figure 1.3). All domains 
are functional in the course of inflammation through apoptosis, cytokine secretion, 
regulation of transcription and cytoskeletal signaling [22].  
 
Figure 1.3 : The structure of pyrin protein. Interacting proteins are also shown [20] 
PYD domain consists of 90 amino acids at the N-terminal of pyrin protein. It is a 
member of a superfamily, which includes caspase recruitment domain (CARD), 
death domain (DD) and death effector domain (DED). About 20 proteins, which 
have role in inflammation or apoptosis, contain the PYD domain. Pyrin protein has 
homotypic interaction with other proteins, which have PYD domain by PYD/PYD 
interaction [4, 24, 25]. Apoptosis-associated speck-like protein (ASC) is one of the 
proteins that interact with pyrin by PYD/PYD interaction. ASC protein, which is the 
adaptor protein in inflammasome, has PYD domain at the N-terminal and CARD 
domain at the C-terminal that binds to caspase-1. Pyrin has role in activation of  
 6
caspase-1, which has proteolytic activation of precursor cytokines such as IL-1β, IL-
18, IL-33 and maturation of IL-1β, which has role as pyrogenic cytokine through 
interaction with ASC protein (Figure 1.4). In addition, it is shown that pyrin activates 
NF-κB through regulation of caspase-1 [26, 27]. 
Another protein in the inflammasome structure that interacts with ASC protein is 
cyropyrin (also known as NALP3, NLRP3, CATERPILLER 1.1) which is a member 
of NALPs family. Cyropyrin has three domains, which are effector-binding domain 
at the N-terminal (PYD domain), nucleotide binding site (NBS) domain of the 
NACHT subfamily (NACHT domain) and leucine-rich repeat domain at the C-
terminal (LRR domain). Mutation of cyropyrin cause three autoinflammatory 
diseases; Muckle Wells syndrome (MWS), Familial Cold Autoinflammatory 
Syndrome (FCAS) and Neonatal Onset Multisystem Inflammatory Disease 
(NOMID). Cyropyrin has function in regulation of IL-1β through binding to ASC via 
PYD-PYD interaction as well as pyrin protein (Figure 1.3) [28].  
 
Figure 1.4 : Pyrin and Cyropyrin have role in inflammation through affecting  
     IL-1β 
Another domain of the pyrin protein is B30.2 which correspond the 10th exon of 
MEFV gene that the mutational hot spot region (M694V, M680I, V726A, M694I).   
 7
It is shown that B30.2 domain of pyrin binds to caspase-1, the inflammasome 
proteins and IL-1β directly. The p10 and p20 subunits of caspase-1 bind to the B30.2 
domain of full-length pyrin strongly and inhibits the conversion of inactive form of 
IL-1β to active form [29]. MEFV mutations at the 10th exon (M694V, M680I and 
V726A) cause less interaction between B30.2 domain and p10 and p20 subunits of 
caspase-1 and induction inflammation through preventing IL-1β activation (Figure 
1.5). Chae et. al. showed that pyrin is a substrate of caspase-1 which cleaves pyrin at 
Asp330 to make 330 residue N-terminal fragment which includes PYD and bZIP 
domain and activates NF-κB without ASC and 451 residue C-terminal fragment. 
Caspase-1 cleavages mutant pyrin more effective than wild type pyrin. However, 
pyrin function has not been clear, all these studies show that pyrin acts as both pro-
inflammatory and anti-inflammatory [30]. 
 
Figure 1.5 The direct interaction between B30.2 domain of pyrin and 
      p10 and p20 domains of caspase-1 [28] 
These studies showed that there is association between mRNA level of MEFV and 
FMF, as well as mutation of MEFV. However, there are many studies about MEFV 
gene and pyrin protein, mRNA studies are very deficient. Transcription level of gene 
is changed via DNA methylation as well as gene mutations. 
1.3 Epigenetic Mechanisms 
Epigenetic is described as functionally changing of genome without nucleotide 
sequence differences (Waddington, 1942). These changes include DNA methylation, 
histone modifications and non-coding RNAs. Epigenetic changes, which are 
generally reversible have role on cellular mechanisms such as development, 
differentiation, X-chromosome inactivation, imprinting, T-cell function and gene 
silencing [31]. 
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1.3.1 DNA Methylation 
DNA methylation is the most common epigenetic mechanism. In eukaryotic 
organisms, DNA methylation occurs at the cytosine bases in the CpG islands which 
describe as genomic region that contain CpG clusters with CG dinucleotides above 
55%. Most of the CpG dinucleotides are condensed at the promoter of gene [32]. In 
addition to methylation of CpG islands, it is showed the methylation in non-CG 
context [33]. Binding of the methyl group to cytosine base is catalyzed by DNA 
metyhltransferases (DNMTs). Methyl group is transferred from S-adenosylmethione 
(SAM) to fifth carbon of cytosine nucleotide by DNMTs (Figure 1.6). Various 
DNMTs were identified which are DNMT1, DNMT2, DNMT3a and DNMT3b. 
DNMT1 has role at the replication fork to copying methylation pattern of parental 
DNA to synthesized DNA in replication. DNMT3a and DNMT3b carry out de nova 
methylation at the unmethylated area. Nevertheless, DNMT2 has only weak DNA 
methyltransferase activity in vitro, it methylates tRNA efficiently [34].  
 
Figure 1.6 : Methylation of cytosine by DNMT 
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1.3.2 Histone Modification 
Another epigenetic change is histone modification, which is acetylation, methylation, 
phosphorylation and ubiquitylation. The most studied histone modifications are 
acetylation and methylation. Five types of histone proteins, which are H1, H2A, 
H2B, H3 and H4, make nucleosome and 146 bp DNA surround it to form chromatin 
structure [35]. Normally, electrostatic attraction between positively charged histone 
protein and negatively charged DNA causes chromatin compaction and reduces gene 
expression. Addition of acetyl group by histone deacetylases (HDAC) to histone tails 
conduce to open confirmation of chromatin and induce gene expression via changing 
charge of histone protein. It is shown that histone modifications and DNA 
methylation are associated each other and indicate chromatin remodeling 
mechanism, thus gene expression is changed by alteration of  packaging of chromatin 
structure (Figure 1.7) [36]. 
 
Figure 1.7 : Histone modifications 
1.3.3 Non-Coding RNAs 
In addition to DNA and chromatin modification, non-coding RNAs (nc-RNAs) 
which are not translated to proteins have important roles at the regulation of 
expression. They affect transcriptional and post-transcriptional gene silencing. Non-
coding RNAs contain micro RNAs (miRNAs), small nuclear RNAs (snRNAs), small 
nucleolar RNAs (snoRNAs), repeat associated siRNAs (rasiRNAs) [31]. Recent 
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studies show the association between ncRNA disruptions and human diseases. 
miRNA expression was found abnormal in some cancers, such as liver, colon, breast, 
hematopoietic and brain cancers or in Alzheimer’s disease and cardiovascular 
diseases. Also, there is a relationship between the loss of specific miRNA loci and 
Prader-Willi syndrome which is induced by the loss of imprinting on chromosome 
15q11-q13 [37].  
1.3.4 Regulation of Gene Expression by DNA Methylation 
Gene expression is commonly regulated via DNA methylation in mammalian cells. 
Methylated CpG islands are generally located at the promoter region of gene and are 
normally unmethylated. DNA methylation of promoter region regulates gene 
expression via directly inhibiting binding of transcription factor or repressing 
chromatin remodeling [38]. Recent studies show that abnormal methylation pattern at 
the promoter site is relevant to expression changing which cause to develop some 
diseases, such as cancer, autoinflammatory diseases [31, 39]. For example, 
hypomethylated promoter of tumor suppressor gene is associated with hepatocellular 
cancers [40], breast cancer [41]. In addition to promoter methylation, recent studies 
emphasize the importance of intronal or exonal CpG islands methylation at the 
regulation of transcription [42, 43]. It is shown that the second exon of bcl-2 gene is 
methylated abnormally in colorectal cancer patients [44]. 
In normal cell, DNA methylation occurs CpG islands at the repetitive genomic 
regions, such as satellite DNA, transposable elements [39]. The effect of intragenic 
methylation to transcription efficiency was studied by Lorincz et. al. and they found 
that the transcription efficiency decreases slightly at the methylated region 
downstream of promoter, compared to unmethylated region. In addition, RNA 
polymerase II (Pol II) was decreased at the methylated region downstream of 
promoter, despite that there was no difference of Pol II at the methylated or 
unmethylated region of promoter site. As a result, they suggested that methylation at 
the downstream of promoter does not affect transcriptal initiation but decreases 
transcriptional elongation [45].   
Also, Lister et. al. showed the methylation pattern at the non-CG context by new 
single-base-resolution DNA methylation map. They carried out bisulfate sequencing 
(BS-Seq) at the human embryonic stem cells and fetal fibroblasts. They observed that 
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99.98% of methylated cytokines are located at the CpG island in fibroblast. Besides 
that they detected abundant DNA methylation at the non-CG context which is 25% 
of all methylcytosines. They suggested that methylation of cytosine at the non-CG 
context might be a general feature of human embryonic cell. In addition, they 
showed the absence of methylation status at the non-CG context while conserved 
methylation at the CpG island at the differentiation of the embryonic stem cell. 
Methylations at the non-CG context are reappeared at the pluripotent stem cell [45]. 
Recently, the effects of epigenetic mechanisms on inflammatory responses are began 
to be questioned. In T cell, normally methylated region at the promoter of the IL-2 
gene is demethylated shortly for increase IL-2 expression. Also, H3 acetylation 
occurs at the IL-4 and IL-13 gene cluster while differentiation of CD4 T cells to T 
helper 2. Epigenetic variability at the genes which produce inflammatory molecules 
or repress the producing of inflammatory molecules regulates immune or 
inflammatory responses [36]. These results are suggested the importance of 
epigenetic mechanisms at the inflammatory diseases. For example, Neil et. al. found 
one unmethylated CpG pattern at the IL-6 gene in RA patients, compared to healthy 
control. It is shown that methylation of this CpG site inhibits binding of nuclear 
proteins to DNA. They suggested that hypomethylation of the CpG site enables the 
binding of transcriptional factors to specific region at the DNA, thus expression of 
IL-6 are increases [31]. 
1.4 Aim of the Study 
Some studies indicate aberrant MEFV expression may cause the pathology in FMF. 
Since methylation is an important mechanism in regulating expression, methylation 
of the CpG island at the second exon of MEFV gene might have a role in FMF 
pathology. The aim of this study was to compare methylation levels of second exon 
of MEFV gene in FMF patients and healthy controls. Also we wanted to correlate 
methylation with expression levels within and between groups. Additionally, in vitro 
studies were done using pCMV-C-Luc reporter assay to determine expression level 
of MEFV by using two different constructs, which are fully and partially spliced 
forms of second exon of MEFV and their methylated forms. Those constructs were 
transfected into HeLa cell lines and their transcription levels were quantified 
luminometrically.  
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2.  MATERIAL AND METHODS 
2.1 Materials and Laboratory Equipment 
2.1.1 Used Equipments 
The laboratory equipment used in this study is listed in Appendix A. 
2.1.2 Used Chemicals, Enzymes, Markers and Kits 
The chemicals, enzymes and markers used are given in Appendix B with their 
suppliers. The compositions and preparation of buffers and solutions are given in 
Appendix C. The kits used and their suppliers are given in Appendix D. 
2.2 Sample Selection 
The study group was composed of FMF patients who came to Pediatric Polyclinic of 
Cerrahpaşa Medical Faculty, Istanbul University. The control group was chosen 
among children who came to the clinic either for a general check up or diagnosed 
with a non – inflammatory disease. The age of the children in the patients or healthy 
group is between 2 to 17.  
The Ethics Review Committee of Istanbul University Cerrahpaşa Medical Faculty 
approved the study. The parents of children were informed and permission forms 
were fulfilled. After that, the blood samples were collected in 4 cc vacuum tubes 
containing EDTA and were kept at 4 °C for maximum two hours for prevention of 
RNA degradation.  
2.3 DNA Isolation from Whole Blood 
The DNA isolation was done by DNA Isolation Kit for Mammalian Blood (Roche). 
The isolated DNAs were used for genotyping and methylation analysis.  
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For DNA isolation, approximately 3 ml blood sample was used. 9 ml Red Blood Cell 
Lysis Buffer was added to blood sample and the mixture was shaken at room 
temperature for 10 minutes. The tubes containing mixture were centrifuged at 875 X 
g for 10 minutes. After centrifugation, the red supernatant was removed carefully and 
white pellet was homogenized by vortex. 1.5 ml White Cell Lysis Buffer was added 
on white pellet and was incubated at 37 °C for 15 minutes. The samples were 
transferred to the sterile tubes. 780 µl Protein Precipitation Solution was added to 
each sample and mixed about 15 second by vortex. The samples were centrifuged at 
12.000 X g for 10 minutes. The supernatant, which contained DNA, was transferred 
15 ml falcon tube. 2 volumes absolute ethanol was added to supernatant and mixed 
gently until the liquid remained no cloudy. Precipitated DNA strand was transferred 
by sterile pipette tip from absolute ethanol to 1 ml 70% ethanol and inverted several 
times. The sample was centrifuged at 875 X g for 5 minutes and the supernatant was 
discarded. After DNA pellet was dried at room temperature, 300 µl TE buffer was 
added to DNA pellet and incubated at 65 °C for about 30 minutes. The samples were 
kept 4 °C for short term and -20 °C for long-term storage. 
DNA concentration was calculated by the NanoDrop® ND-1000 UV-Vis 
Spectrophotometer. DNAs were diluted to 50 ng/µ l for working aliquots. 
2.4 RNA Isolation from Whole Human Blood 
Total RNAs of the groups were used for gene expression analysis. Prevention of 
RNA degradation in vacuum tube with EDTA, RNA was tried to be isolated 
immediately. Because of that blood samples in tubes were kept at 4 °C for maximum 
3 or 4 hours. The tubes and pipette tips used in RNA isolation were made RNase free 
by DEPC treatment. Total RNA was isolated from whole human blood by High Pure 
RNA Isolation Kit (Roche).  
1 ml Red Blood Cell Lysis Buffer was added to a sterile 1.5 ml reaction tubes. 500 µl 
peripheral blood was added into tubes and mixed. The tubes were shaken at room 
temperature for 10 minutes. Then the tubes were centrifuged at 500 X g for 5 
minutes. After centrifugation, red supernatant was removed carefully with sterile 
pipette. Again 1 ml Red Blood Cell Lysis Buffer was added to white pellet and 
mixed by flicking. The tubes were again centrifuged at 500 X g for 3 minutes and the 
supernatant was removed carefully. 200 µl PBS was added into white pellet and 
 15
resuspended. Also 400 µl Lysis/Binding Buffer was added and mixed by vortex for 
15 seconds. The sample was transferred to filter tube and centrifuged at 8.000 X g for 
15 seconds. After centrifugation, fluid was discarded. For each sample 90 µl DNase 
incubation buffer and 10 µl DNase I were mixed in a separate tube. The mixture was 
added into filter tube and incubated at room temperature for 15 minutes. After 
incubation, 500 µl Wash I Buffer was added into filter tube and centrifuged at 8000 
X g for 15 seconds and the fluid were discarded. Then 500 µl Wash II Buffer was 
added into filter tube and centrifuged at 8.000 X g for 15 seconds and the fluid were 
discarded. 200 µl Wash II Buffer was added again into filter tube and centrifuged at 
maximum speed for 2 minutes and the fluid was discarded with collection tube. The 
filter tubes were inserted 1.5 ml microcentrifuge tubes and 70 µl Elution Buffer was 
added. The tubes were centrifuged at 8.000 X g for 1 minute. The eluted RNAs were 
used for cDNA synthesis and stored at –80 °C for later usage. 
2.5 cDNA Synthesis 
Because of easily degradation of RNA, cDNA was used for MEFV expression 
analysis with Real-Time PCR. For prevention of RNA degradation, cDNA synthesis 
was done followed total RNA isolation by using Transcriptor First Strand cDNA 
Synthesis Kit (Roche).  
1 µl of 50 pmol/µl anchored oligo (dT) primer, 5 µl of PCR grade dH2O were added 
into sterile PCR tubes. 7 µl total RNA isolated previously was added to tubes and 
mixed by pipettes. Tubes were placed in a thermal cycler and denatured at 65 °C for 
10 minutes. After denaturation, mixture was taken on ice immediately. 4 µl 5X 
Transcriptor Reverse Transcription reaction buffer, 0.5 µl 40 U/µl Protector RNase 
inhibitor, 2 µl dNTP mix (10 mM each), and 0.5 µl 10 U/µl Transcriptor Reverse 
Transcriptase were mixed separate tube and added to mixture containing RNA 
samples. For inactivation of Reverse Transcriptase, the samples were incubated at 55 
°C for 30 minutes and at 85 °C for 5 minutes in thermal cycler. The reaction was 
stopped by placing the tubes on ice. Synthesized cDNAs were stored at -20 °C for 
longer periods. 
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2.6 Genotyping 
2.6.1 Polymerase Chain Reaction (PCR) 
The target sequences within second and tenth exon of MEFV were amplified by 
Polymerase Chain Reaction (PCR). For PCR reaction, isolated genomic DNA was 
used as a template. General PCR mix which was used to amplify target DNA 
sequence is as in table 2.1. 
Table 2.1 General PCR mix 
Stock Concentration PCR Ingredient           Volume         Final 
Concentration 
    
10 X MgCl2 free 
TaqBuffer 
2 µL              1 X 
25 mM MgCl2 1.5 µL 1.875 M 
2.5 mM dNTP Mix 0,32 µL 40 µM 
10 pmol/µL Forward Primer 1 µL 0.5 µM 
10 pmol/µL Reverse Primer 1 µL 0.5 µM 
- dH2O 8.7 µL - 
5 U/ µL Taq Polymerase 0.2 µL 0.05 U/µL 
5 M Betain 4 µL 1 M 
50 g/ µL Template DNA 2 µL 100 ng/µL 
TOTAL  20 µL  
2.6.2 Oligonucleotide Primers 
Six oligonucleotide primers were used to amplify target sequences of MEFV which 
contain five variant site; M694V, M680I, V726A, M694I and E148Q. The primers 
were selected from previous studies. The sequences of primers are given table 2.2. 
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Table 2.2 Oligonucleotide primers 
Variation Primer Sequence         
Amplicon                  
Size 
   
M694V 
 
 
 
F-5'-TACTGGGTGGTGAT*CAT-3' 
 R-5'-AGGGCTGAAGATAGGTTGAA-3' 
215 bp 
 
M680I F-5'-TGTATCATTGTTCTGGGCTCT-3'  
R-5'-AGGGCTGAAGATAGGTTGAA-3'   
360 bp 
V726A F-5'-TGTATCATTGTTCTGGGCTCT-3' 
R-5'-AGGGCTGAAGATAGGTTGAA-3' 
360 bp 
 
M694I F-5'-TGTATCATTGTTCTGGGCTCT-3'    
R-5'-CTGGACGCCTGGTACTCATTTTT*C-3 
195 bp 
 
E148Q F-5'-ATATTCCACACAAGAAAACGGC-3'         
R-5'-GCTTGCCCTGCGCG-3' 
 
244 bp 
     
2.6.3 PCR Conditions 
PCR conditions were optimized previous studies. Except of E148Q PCR, all PCR 
conditions were similar.  Only annealing temperatures were different in the 
conditions because of using different primers. PCR programs for each SNP are given 
in table 2.3, 2.4 and 2.5. 
Table 2.3 PCR program for M694V, M680I and V726A 
PCR Phase Temperature Time Repeat 
    
Initial Denaturation 96 °C   5 min. 1 
Denaturation 96 °C   30 sec.  
Annealing 55 °C   30 sec. 35 
Extension 72 °C   30 sec.  
Final Extension 72 °C    10 min. 1 
Final Hold 4 °C ∞  
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Table 2.4 PCR program for M694I 
PCR Phase Temperature Time Repeat 
    
Initial Denaturation 96 °C   5 min. 1 
Denaturation 96 °C   30 sec.  
Annealing 59 °C   30 sec. 35 
Extension 72 °C   30 sec.  
Final Extension 72 °C    10 min. 1 
Final Hold 4 °C ∞  
 
Table 2.5 PCR program for E148Q 
PCR Phase Temperature Time Repeat 
    
Initial Denaturation 96 °C   5 min. 1 
Denaturation 96 °C   30 sec.  
Annealing 64 °C   30 sec. 5 
Extension 72 °C   30 sec.  
Denaturation 96 °C   30 sec.  
Annealing 62 °C   30 sec. 35 
Extension 72 °C   30 sec.  
Final Extension 72 °C    10 min. 1 
Final Hold 4 °C ∞  
 
DNA fragment lengths, which amplified PCR, were between 195 – 360 bp. These 
PCR products can be seen at 1% agarose gel. 1% mini or midi agarose gels were 
prepared for detection of PCR products. For mini gel preparation, 0.5 g agarose was 
added to 50 ml 1 X TAE buffer and 0.25 µl ethidium bromide (EtBr) was added. For 
midi gel preparation, 2 g agarose and 0.75 µl EtBr were added to 200 ml 1 X TAE 
buffer. 5 – 6 µl PCR product and 1 µl 6 X loading dye (Fermentas) were mixed and 
loaded into wells of the gels. MassRuler DNA ladder low range (Fermentas) was 
used as standard in gel electrophoresis. The gels were run at 120 V for about 40 min. 
and analyzed under UV light with transilluminator. The pictures of gels were taken 
with UV PhotoMW software.  
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Table 2.6 Restriction enzyme mix 
PCR Phase Repeat 
  
10 X Restriction Buffer 2 µL 
dH2O 5 µL 
Restriction Enzyme 1 µL 
Amplicon 12 µL 
 
 
The mixture were kept at 37 °C for overnight and after that for inactivation of 
restriction enzyme, incubated at 80 °C for 30 minutes. Used restriction enzymes and 
expected fragment sizes were given in the table 2.7. 
Table 2.7 Used restriction enzymes and expected fragment sizes 
Variation Restriction Enzyme Fragment  Size 
   
M694V 
 
Pag I Wild Type: 2 fragments (200 – 15 bp) 
Mutant: 1 fragment (215 bp) 
M680I Hinf I Wild Type: 2 fragments (126 – 234) 
Mutant: 1 fragment (360) 
V726A Alu I Wild Type: 1 fragment (360) 
Mutant: 2 fragments (320 – 40) 
M694I Mbo II Wild Type: 1 fragment (195) 
Mutant: 2 fragments (182 – 13) 
E148Q Ava I Wild Type : 3 fragments (92 – 83 – 69) 
Mutant: 2 fragments (161 – 83) 
 
 
After restriction enzyme digestion, PCR products were run on agarose gel. 
According to product sizes 2%, 3.5% and 4% agarose gels were prepared. To analyze 
M680I and V726A SNPs 2%, M694V and M694I 3.5%, E148Q 4% agarose gels 
were used. 12 µl PCR products were mixed with 2 µl 6 X loading dye and loaded 
into wells of gels. The gels were run at 120 V for about 40 minutes and band sizes 
were seen under UV light.  
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2.7 Expression Analysis 
2.7.1 Real-Time PCR for Quantification of MEFV Expression 
The real – time PCR was done by LightCycler® TaqMan Master Kit (Roche) and 
performed at Roche LightCycler® 2.0 instrument. Primer and probes were designed 
at Universal ProbeLibrary website of Roche (www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp?id=UP030000). B2M gene was used as reference 
gene. For standard curve preparation, cDNA sample were used in 4 different 
concentrations, as undiluted, 1:10 diluted, 1:100 diluted and 1:1000 diluted forms. 
Real – Time PCR mixtures and Real – Time PCR program are given table 2.8, table 
2.9 and table 2.10. 
Table2.8 Real – time PCR mixture for MEFV 
Ingredient Concentration Volume Final 
Concentration 
    
TaqMan Master Mix 5 X 4 µL 1 X 
MEFV Forward Primer 10 µM 0.2 µL 250 nM 
MEFV Reverse Primer 10 µM 0.2 µL 250 nM 
UPL Probe #8 10 µM 0.2 µL 100 nM 
dH2O  - 10.4µL - 
   cDNA Template - 5 µL - 
 
Table 2.9 Real – time PCR mixture for B2M as reference gene 
Ingredient Concentration Volume Final 
Concentration 
    
TaqMan Master Mix 5 X 4 µL 1 X 
B2M Primer Mix 10 µM 0.2 µL 250 nM 
UPL Reference Gene Assay 10 µM 0.2 µL 100 nM 
dH2O  - 10.6µL - 
   cDNA Template - 5 µL - 
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Table 2.10 Real – Time PCR program for MEFV and B2M 
Analysis Phase Temperature Time Repeat 
    
Pre-Incubation 95 °C 10 min. 1  
Denaturation 95 °C 10 sec.  
Annealing 60 °C 30 sec. 45 
Extension 72 °C 1 sec.  
Cooling 40 °C 30 sec. 1 
 
2.7.2 Relative Quantification and Statistical Analysis 
The comparative CT (also known as ∆∆CT) method is used to calculate relative gene 
expression. This method is a mathematical model for calculation of gene expression 
and does not require the standard curve. The ∆∆CT method is useful to assay large 
number of samples. It should only use when the PCR efficiencies of the target and 
reference genes are relatively equivalent. For each sample, the ∆CT value was 
calculated by subtraction CT value of target gene from CT value of reference gene 
(∆CT= CT of β2M - CT of MEFV). 2-∆CT value indicates the fold change between  
target gene and reference gene [44].  
The 2-∆CT value of FMF patients group and healthy control group were analyzed 
statistically by using Student’s t test, Chi square analyses using SPSS statistical 
analyses program (v.16). 
2.8 In Vitro Expression Analysis 
MEFV cDNA constructs containing exon 2 variants were previously cloned by our 
group. Two different spliced transcripts of MEFV were cloned into phCMV-C-
Luciferase (phCMV-C-Luc) which is a reporter vector to quantify the binding 
activity in vivo through using luciferase assay. These vectors were transfected to 
HeLa cells. 
Stock cells were taken from -80 °C and melted at room temperature. Cells were 
transferred into 10 ml 37 °C warmed 10% DMEM centrifuged at 3000 rpm for 5 
minutes. 10% DMEM of consists 44.5 mL DMEM, 0.5 mL L-Glutamin, 0.1 mL 
penicillin/streptomycin (Pen/Strep) and 5 mL fetal bovine serum (FBS). HeLa cells 
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were cultured for two days in 37 °C and 5% CO2 incubator. 50.000 cells were seeded 
into per well at 24 well tissue culture plate one day before transfection. 1 µg plasmid 
DNA was diluted in the DMEM and 3 µl Transfast (Promega) was added. The 
mixture was incubated at room temperature for 15 minutes. Each transfection was 
performed as triplicates. The medium was removed from cells and transfection 
mixture was added. The cells were incubated for 90 minutes in 37 °C and 5% CO2 
incubator. After incubation, the transfection mixture was removed and 500 µl growth 
media was added into each well and cells were incubated. 48 hours after transfection 
luminometrical measurement was done by Dual-Luciferase® Reporter Assay System 
(Promega). The activities of firefly (Photinus pyralis) and renilla (Renilla reniformis) 
luciferases were measured consecutively. 60 µl 1X passive lysis buffer was added 
into each well and the cells were lysed. 50 µl LAR II was added into one well of 
luminometer plate and 50 µl lysate was loaded into the well. Firefly luciferase 
luminescence was measured. 50 µl Stop-Glo® reagent was added and renilla 
luciferase luminescence was measured immediately. The procedure was performed 
for each sample and results were reported.  
2.9 Methylation Analysis 
2.9.1 CpG Island Analysis of MEFV 
CpG island of MEFV gene was analyzed by using CpG island searcher software of 
University of Southern California (http://cpgislands.usc.edu). An illustration of the 
program screen is given in figure 2.1. 
 
 
Figure 2.1: Illustration of CpG island software 
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2.9.2 Bisulfite Treatment 
For quantify of DNA methylation level, unmethylated cytosine is converted into 
uracil by bisulfite treatment method whereas methylated cytosine is not converted. 
Consequently, two different DNA sequences, for methylated and unmethylated, were 
made. Bisulfite treatment was done according to protocol by supplier of the EZ DNA 
Methylation – GoldTM Kit (Zymo Research).  
Inception amount of DNA is important because of the efficiency of bisulfite 
conversion. 1 µg DNA was dissolved in 20 µl dH2O and used for each reaction 
(recommended 1 µg to 2 µg). 130 µl CT Conversion Reagent was added to 20 µl 
DNA sample and mixed by flicking. The tube was placed in thermal cycler and 
incubated as following; 98 °C for 10 minutes and 64 °C for 2.5 hours. Preferentially, 
the sample can stored at 4 °C for 24 hours. 600 µl M – Binding Buffer was added to 
a Zymo – Spin TM IC Column tube and the sample was loaded into the Zymo – Spin 
TM
 IC Column tube which contain the M – Binding Buffer and mixed several times. 
The tube was centrifuged at maximum speed for 30 seconds and flow-through was 
discarded. 100 µl M – Wash Buffer was added to column and centrifuged at 
maximum speed for 30 seconds and flow-through was discarded. 200 µl M – 
Desulphonation Buffer was added to column and sample was incubated at room 
temperature for 15 – 20 minutes. After incubation, the tube was centrifuged at 
maximum speed for 30 seconds. 200 µl M – Wash Buffer was added to column and 
centrifuged at maximum speed for 30 seconds and this step is repeated again. 
Column was placed into 1.5 ml microcentrifuge tube. 10 µl M – Elution Buffer was 
added to the column matrix and tube was centrifuged at maximum speed for 30 
seconds. The DNA was stored at – 20 °C for later use or – 80 °C for long-term use. 
2.9.3 Real-Time PCR for Quantification of MEFV Methylation 
MethyLight assay was used to measure methylation status of second exon of MEFV 
gene [45]. LightCycler® TaqMan Master Kit from Roche and performed at Roche 
LightCycler® 2.0 instrument were used for this study [46]. Probes and primers were 
designed Universal ProbeLibrary website of Roche (www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp?id=UP030000). Bisulfite treated DNA was used 
as a template. For each sample, One set of primer was designed for methylated form 
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of DNA sequence. In addition, ACTB primers were used as reference gene, which 
were designed both methylated and unmethylated form of DNA sequences. To 
confirm the efficiency of bisulfite treatment, genomic DNAs were performed for 
each sample. For standard curve preparation, fully methylated DNA sample was used 
four different concentrations. Also General Real – Time PCR mixture and program 
are given in the table 2.11 and table 2.12 below. 
Table 2.11 : Real – time PCR mixture 
Ingredient Concentration Volume Final 
Concentration 
    
TaqMan Master Mix 5 X 4 µL 1 X 
Methylated Forward Primer 10 µM 1 µL 500 nM 
Methylated Forward Primer 10 µM 1 µL 500 nM 
UPL Probe #7 10 µM 0.4 µL 200 nM 
dH2O  - 10.6µL - 
   cDNA Template - 5 µL - 
 
Table 2.12 : Real-Time PCR program 
Analysis Phase Temperature Time Repeat 
    
Pre-Incubation 95 °C 10 min. 1  
Denaturation 95 °C 10 sec.  
Annealing 60 °C 30 sec. 45 
Extension 72 °C 1 sec.  
Cooling 40 °C 30 sec. 1 
 
2.9.4 Relative Quantification and Statistical Analysis 
The relative quantification and statistical analysis were done same way as expression 
analysis. The comparative CT method is used to calculate methylation level and FMF 
patients group and healthy control group results were analyzed statistically by using 
Student’s t test, Chi square analyses using SPSS statistical analyses program (v.16). 
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3.  RESULTS 
3.1 Demographic Data of the FMF Patients 
Blood samples were collected from 51 FMF patients and 11 healthy controls. The 
FMF patients group consists of 50% of female and 50% of male. None of the patients 
had attacks of serositis and fever at the time of samples collection. The healthy 
control group was composed of mostly male (81%) and had a mean age of 8±3,6. 
Clinical information of FMF patients are shown at the table 3.1. 
Table 3.1 : Clinical information of FMF patients 
FMF Patients (N=51) % Percentage 
Female 50 % 
Male 50 % 
Mean Age 10±4 (range 2-20) 
Amyloidosis - 
Usage of Colchicine 100 % 
Response to Colchicine 100 % 
3.2 Genotype Analysis Results 
The genotype analysis was done by comparing agarose gel results with the expected 
restriction enzyme digestion patterns and allele counting. PCR and restriction 
enzyme results of sample for each mutation analysis are given Appendix E. 
3.3 Statistical Mutation Analysis 
MEFV allele frequencies were compared between FMF patients and healthy controls. 
The observed allele frequencies are given in table 3.1. Significantly, differences were 
found between the mutations frequencies of FMF patients and healthy controls. 
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Table 3.2 : Frequency of five common MEFV mutations in FMF patients and                   
healthy control 
Variation FMF Allele Frequency 
n=102 
Healthy Control Allele Frequency 
n=22 
   
M694V 
 
45 % - 
M680I 5.8 % 13.6 % 
V726A 1.9 % 4.5 % 
M694I 
 
E148Q 
- 
 
6.8 % 
- 
 
4.5 % 
*TOTAL            59.5%           22.6% 
*Mantel Haenszel chi square= 9.912 (p= 0.0016), Odds Ratio: 2.7689  
   95% CI: 1.7302< O.R. <14.7894 
3.4 Expression Analysis Results 
Singleplex PCR reactions for MEFV and β2M were done separately. The standard 
curve settings were done successfully and the error rates of the Real-Time PCR 
reaction were about 1%, which is among acceptable value, and the efficiencies of the 
reactions were about two, which are given in table 3.2. The standard curves of 
MEFV and β2M are given in figures 3.10 and 3.11 below. 
Table 3.3 : Error rates and efficiencies of MEFV and B2M real-time PCR reactions 
 MEFV B2M 
   
Error Rate 0.01 0.004 
Efficiency 1.98 2.4 
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Figure 3.1 : Standard curve for MEFV 
 
Figure 3.2 : Standard curve for B2M 
Relative expression level was calculated for each sample by ∆CT method. In the 
overall data, the lowest mRNA levels was observed in the FMF patient with M694V 
and M680I heterozygous mutant genotype (0.00041 Relative Expression Units) and 
highest mRNA level was found in the healthy control with no mutation (0.02758 
Relative Expression Units). When we compared the expression level results from 51 
FMF patients and 11 healthy controls, we observed two fold decrease in mRNA 
levels of MEFV gene in FMF patients compared to healthy controls (p=0.031). The 
graph shows the relative expression level of MEFV in FMF patients and healthy 
controls are given figure 3.12. 
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Figure 3.3 : Comparison of expression level of MEFV in FMF patients and  
      healthy controls 
In additionally, MEFV variants of M694V, M680I, V726A and E148Q were 
separately analyzed for expression levels. The relative expression of MEFV mRNA 
level was lower in FMF patients with M694V/n than healthy controls but higher than 
FMF patients with another mutations or without mutation (N=3, 0.00353 relative 
expression level). The graph showing expression levels of MEFV gene among FMF 
patients group is shown in figure 3.13. 
 
*M694V/n-M680I/n (3), M694V/M694V-E148Q/n (3), M694V/n-E148Q/n, 
M694V/M694V-M680I/n,  M694V/n-V726A/V726A 
Figure 3.4 : Comparison of expression level of MEFV in FMF patients  
         with mutations and without any mutations 
N=14     N=5      N=2       N=1       N=1       N=1     N=9      N=18     N=51  N=11 
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The relative expression of MEFV was also compared between FMF patients with 
mutations and FMF patients without mutations. There is no significantly difference 
between two groups (p= 0.70). Also, expression levels were compared between the 
healthy controls with mutations and without any mutations. Significantly difference 
was not found also in these two groups (p= 0.59). The graphs are shown in figure 
3.14 and 3.15.  
 
   Figure 3.5 : Comparison of expression level of MEFV in FMF patients with  
       mutations and without mutations 
 
 
 
Figure 3.6 : Comparison of expression level of MEFV in healthy controls  
       with mutations and without mutations 
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3.5 CpG Island Analysis Results 
MEFV gene has a 51 % CG content overall genomic DNA and this value is 59% at 
the cDNA. The second exon of MEFV was found to contain high CG content (66%). 
When MEFV gene was analyzed for CpG island (CpG island searcher software of 
University of Southern California, http://cpgislands.usc.edu) a 998 bp CpG island 
was found at the second exon of MEFV gene (Figure 3.16). Within this CpG island, 
568 bp region containing 41 CpG sites which corresponds to the second exon of gene 
was selected for methylation analysis. CpG sites are given in Appendix F. 
 
Figure 3.7 : CpG island on the MEFV genomic DNA sequence 
3.6 In Vitro MEFV Expression Analysis 
Two exon 2 variants of MEFV which are fully spliced and alternatively spliced 
forms were transfected into HeLa cells to analyze expression level of MEFV in vivo. 
In addition, methylated forms of these two constructs were analyzed. For each 
sample light units of friefly and renilla were proportioned to calculate expression 
level of MEFV. About two fold increased MEFV expression level was observed in 
the fully spliced form of second exon of MEFV gene to compare partially spliced 
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form. Approximately two fold increase in MEFV expression level in second exon 
fully spliced form of MEFV compared to second exon partially spliced form of 
MEFV.  In addition, methylated form of these constructs were analyzed and we 
observed that methylation of MEFV cDNA decreases the expression level of MEFV 
gene. The graph is given figure 3.17. 
 
Figure 3.8 : In vitro expression levels of exon2 variants of MEFV 
3.7 Real-Time Results for Methylation Status 
Methylation levels of MEFV gene were compared between FMF patients and healthy 
control groups. Bisulfite treated DNA was used as a template to calculate MEFV 
methylation level and ACTB level which is used as an internal control. Real-Time 
PCR were done with primers and probes, which are specific to methylated 
sequences. Genomic DNA was used as a control for bisulfite treatment efficiency in 
each reaction. Fully methylated DNA (Millipore) was used in three different 
concentrations, as undiluted, 1:10 diluted and 1:100 diluted forms to prepare standard 
curve. The error rates of the Real-Time PCR reaction were about 1% for target gene 
and 0.1% for reference gene and the efficiencies of the reactions were about two for 
both gene. The standard curves of MEFV and ACTB are given in figures 3.18 and 
3.19 below. 
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Figure 3.9 : Standard curve for MEFV in MethyLight experiment 
 
Figure 3.10 : Standard curve for ACTB in MethyLight experiment 
 
Bisulfite treatment was seen to be efficient, since no amplification at the genomic 
DNAs of each sample. The methylation levels of samples were calculated by 
comparing to reference gene (∆CT method) in 34 of 51 FMF patients and 10 of 11 
healthy controls. The 2-∆CT value of FMF patients group and healthy control group 
were analyzed statistically by using Student’s t test. There was no significantly 
difference methylation status of MEFV between FMF patients and healthy controls 
(p=0.53, Std. Dev: 1,06). The graph of methylation status of MEFV is given figure 
3.20. 
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     Figure 3.11 : Comparison of methylation levels of MEFV in FMF patients  
and healthy controls 
Methylation levels of MEFV were also compared between FMF patients with 
different mutations and healthy controls. Methylation level of MEFV in FMF 
patients with M694V/M694V, M694V/n, E148Q/n and compound mutations and 
without mutations were higher than healthy children. On the other hand, in FMF 
patients with M680I/n and V726A/n genotype, the methylation levels of MEFV were 
lower compared to healthy controls (Figure 3.21).  
 
*M694V/n-M680I/n (3), M694V/M694V-E148Q/n (3), M694V/n-E148Q/n,    
M694V/M694V-M680I/n,  M694V/n-V726A/V726A 
Figure 3.12 : Comparison of methylation levels of MEFV in FMF patients  
with different mutations and healthy controls 
N=9       N=2    N=1       N=1    N=1     N=11   N=9    N=34  N=10 
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MEFV methylation level was compared between FMF patients with mutations and 
FMF patients without mutations and healthy controls with mutations and without 
mutations. In two analysis, there are no significantly differences were found. The 
graphs are given in figure 3.22 and 3.23.  
 
 
   Figure 3.13 : Comparison of methylation levels of MEFV in FMF patients with    
mutations and FMF patients without any mutations 
 
     Figure 3.14 : Comparison of methylation levels of MEFV in healthy controls 
with mutations and without any mutations 
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Methylation status of second exon of MEFV was compared between FMF patients 
with mutations and without any mutations and healthy controls with mutations and 
without mutations. Methylation status of MEFV was found approximately 1,5 fold 
higher in FMF patients than healthy controls (Figure 3.23). 
 
Figure 3.15 : Methylation status of MEFV 
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4.  CONCLUSION AND DISCUSSION 
The gene for FMF, MEFV, encodes the protein pyrin that is known to have a 
function in inflammation and apoptosis. However, its role for anti-inflammation or 
pro-inflammation is still under question; moreover  there are conflictory results for 
the possible function of mutations on its mRNA expression. 
In this study, we wanted to investigate the expression and methylation patterns of 
MEFV gene. Its expressional patterns in FMF and healthy controls, raises the 
question of whether methylation has a role in its differing expressional patterns 
because of the presence of a CpG islands in the second exon of MEFV. Previous 
studies showed that methylation in the exons of the gene can alter the expression by 
preventing transcriptional elongation (i.e. Lorincz et. al. 2004).  
The present study shows that the expression levels of MEFV gene were significantly 
lower in FMF patients than in healthy controls (p=0.031). Our results are consistent 
with two previous expression studies (Notarnicola et. al., 2002 and Ustek et. al., 
2007). On the other hand, Booty et. al., 2009 showed that there is no significant 
difference in MEFV mRNA expression between FMF patients and healthy controls. 
We also compared the MEFV expression levels between FMF patients with 
mutations and FMF patients with no identified mutations and between healthy 
controls with mutations and healthy controls without mutations. Contrary to 
Notarnicola’s study (2002), we did not observe significantly association between 
mutations and expression levels of MEFV in neither groups; still, the expression 
levels were slightly higher in individuals without mutations. When we analyzed the 
MEFV expression levels according to the type of mutations, the highest expression 
levels of gene was associated to M694V mutations, which is the opposite of the 
previous two results in literature (Notarnicola et. al., 2002 and Ustek et. al., 2007).  
Methylation status of second exon of MEFV gene were not found significantly 
different between FMF patients and healthy controls (p=0.53). However  the 
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methylation status in FMF patients were approximately 1.5 fold higher than healthy 
controls. When we compared the methylation levels of MEFV between FMF patients 
with mutation and FMF patients without mutations, we cannot find a significant 
difference (p= 0.93), however, methylation level were found slightly higher in FMF 
patients without any mutations. Accordingly, the low expression levels of MEFV 
may be related to the higher methylation status of the gene in FMF patients, hence 
more conclusive data is needed to prove the role of methylation on the 
pathophysiology of FMF. 
In this study, we could not find significant association between methylation status of 
second exon of MEFV and expression levels of the gene. As a further aspect, the 
number of samples will be increased to obtain more statistically accurate results. As 
shown in the study of Ustek et. al., 2007, there is a significant difference in the 
relative expression of the MEFV mRNA using the  primers covering 2-3 exons 
between the asymptomatic and inflammatory periods. However no such difference 
was observed when the primers for 7-10 exons are used. Therefore, the expression 
levels of the second exon fully spliced form of MEFV and of the full-length MEFV 
can be compared in future. In addition, the methylation status of MEFV gene in 
asymptomatic and inflammatory periods of FMF patients requires a further analyses.  
Finally, in vitro cell culture studies can be done in the THP-1 cells, which are human 
monocytic cell line, to compare the expression levels of three variants of MEFV, 
which are fully spliced form of second exon, partially spliced form of second exon 
and full-length form of MEFV. 
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APPENDIX A 
 EQUIPMENT 
Centrifuges    Sigma 1-13 B. Braun International 
     Allegra 25R Centrifuge Beckman Coulter 
Electrophoresis equipments E – C mini cell primo EC320 
Gel Documentation System  UVI PhotoMW Version 99.05 for Windows 
Pipettes    Gilson Pipetman 20 µL 200 µl, 1000 µl  
pH meter     Mettler Toledo MP220 
Spectrophotometer PerkinElmer Lambda25 UV/VI Spectrometer 
Thermo cycler     Applied Biosystems GeneAmp PCR  
System 2700 
Corbett PalmCycler  
Techne FTGENE 5D 
Transilluminator   Biorad UV Transilluminator 2000 
Vortex    Herdolph Reax top 
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APPENDIX B 
CHEMICALS 
Agarose    AppliChem 
Boric acid    Amresco 
dNTP     Fermentas 
EDTA     AppliChem 
Ethanol     Riedel-de Haën 
EtBr     Amresco 
MgCl2     Fermentas 
Primers    IDT DNA 
Tris Base    Amresco 
10X PCR Buffer   Fermentas 
 
ENZYMES 
AluI     Fermantas 
AvaI     Fermantas 
HinfI     Fermantas 
MboII     Fermantas 
PagI     Fermantas 
Taq DNA Polymerase  Fermentas 
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MARKERS 
 
Gene RulerTM 1 kb DNA Ladder   Fermentas 
 
 
 
Gene RulerTM DNA Ladder Low Range  Fermentas 
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APPENDIX C  
BUFFERS 
TE Buffer  
Tris base     10 mM 
EDTA     1 mM 
Add ddH2O to 1 liter and adjust the pH to 8.0 
TAE (Tris-Acetic Acid-EDTA) Buffer (10X) 
Tris base    108 g  
Glacial acetic acid   50 mL 
EDTA     40 mL (0.5 M, pH 8.0) 
Add ddH2O to 1 liter and adjust the pH to 8.0 
Mini Agarose Gel (1%)  
Agarose    0.5 g 
TAE buffer (1X)   50 mL 
Add 1.5 µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Midi Agarose Gel (1%)  
Agarose    1.5 g 
TAE buffer (1X)   150 mL 
Add 4.5 µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
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APPENDIX D 
USED KITS 
DNA Isolation  DNA Isolation Kit for Mammalian Blood (Roche) 
RNA Isolation                       High Pure RNA Isolation Kit (Roche) 
cDNA Synthesis  Transcriptor First Strand cDNA Synthesis Kit (Roche) 
Bisulfite Treatment              EZ DNA Methylation Kit (Zymo) 
Real-Time PCR                    LightCycler TaqMan Master Mix (Roche) 
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APPENDIX E 
SAMPLE PCR AND RESTRICTION ENZYME RESULTS 
 
Figure C.1 : M694V PCR result 
 
Figure C.2 : M694V restriction enzyme digestion result 
 
Figure C.3 : M680I and V726A PCR results 
215bp 
360bp 
MV          MM       MM        VV          MV        VV           MM        VV         VV     Marker 
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Figure C.4 : M680I restriction enzyme digestion result 
 
Figure C.5 : V726A restriction enzyme digestion result 
 
Figure C.6 : M694I PCR result 
195 bp 
MM   MM  MM    MI    MM   MI     MM   MM  MM  MM    MM   MM    MM  MM   MI       MM   MM  MM  MM   Marker 
Marker       VV           VV              VA            VV           VV          VV              VV             VV           VV         VV 
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Figure C.7 : M694I restriction enzyme digestion result 
 
Figure C.8 : E148Q PCR result 
 
Figure C.9 : E148Q restriction enzyme digestion result 
 
 
 
Marker      MM      MM      MM        MM     MM     MM     MM       MM      MM    MM        MM 
Marker                 EE               EE                  EQ                 EE               EE              EQ 
244 bp 
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APPENDIX F 
CpG SITES ON Second Exon of MEFV 
 
Methylated        GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
Unmethylated      GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                  ************************************************* ******** * 
 
Methylated        AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
Unmethylated      AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                  ******* ****** *** *** ***** *************** ************* * 
 
Methylated        AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
Unmethylated      AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                  **** ************* ******************* *************** ***** 
 
Methylated        GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
Unmethylated      GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                  ******* * ************* ***** ****** ******** *** ********** 
 
Methylated        TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
Unmethylated      TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                  * ************* ****************** ****** ***** ******* **** 
 
Methylated        GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
Unmethylated      GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                  **** * ******************** ****** **** ******************** 
 
Methylated        TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
Unmethylated      TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                  **** **************** ********** *************************** 
 
Methylated        TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
Unmethylated      TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                  *************** *** **************************************** 
 
Methylated        TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
Unmethylated      TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                  *** *********** ************* *************** ************** 
 
Methylated        TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
Unmethylated      TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
                  *** ************************ 
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